Combined PD-1, BRAF and MEK Inhibition in BRAFV600E Colorectal Cancer: A Phase II Trial

The authors performed a proof-of-concept single-arm phase II clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab, dabrafenib, and trametinib in 37 patients with BRAFV600E colorectal cancer.